FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316581203> ?p ?o ?g. }

• W2316581203 endingPage "32155" @default.
• W2316581203 startingPage "32144" @default.
• W2316581203 abstract "// Quirijn R.J.G. Tummers 1, 5, * , Charlotte E.S. Hoogstins 1, 5, * , Katja N. Gaarenstroom 2 , Cor D. de Kroon 2 , Mariette I.E. van Poelgeest 2 , Jaap Vuyk 3 , Tjalling Bosse 4 , Vincent T.H.B.M Smit 4 , Cornelis J.H. van de Velde 1 , Adam F. Cohen 5 , Philip S. Low 6 , Jacobus Burggraaf 5 , Alexander L. Vahrmeijer 1 1 Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands 2 Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands 3 Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands 4 Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands 5 Centre for Human Drug Research, Leiden, The Netherlands 6 Department of Chemistry, Purdue University, West Lafayette, IN, USA * These authors have contributed equally to this work and share first authorship Correspondence to: Alexander L. Vahrmeijer, email: a.l.vahrmeijer@lumc.nl Keywords: image-guided surgery, fluorescence, folate-receptor alpha, breast cancer, ovarian cancer Received: November 04, 2015     Accepted: February 11, 2016     Published: March 22, 2016 ABSTRACT Introduction: Intraoperative fluorescence imaging of the folate-receptor alpha (FRα) could support completeness of resection in cancer surgery. Feasibility of EC17, a FRα-targeting agent that fluoresces at 500nm, was demonstrated in a limited series of ovarian cancer patients. Our objective was to evaluate EC17 in a larger group of ovarian cancer patients. In addition, we assessed the feasibility of EC17 in patients with breast cancer. Methods: Two-to-three hours before surgery 0.1mg/kg EC17 was intravenously administered to 12 patients undergoing surgery for ovarian cancer and to 3 patients undergoing surgery for biopsy-proven FRα-positive breast cancer. The number of lesions/positive margins detected with fluorescence and concordance between fluorescence and tumor- and FRα-status was assessed in addition to safety and pharmacokinetics. Results: Fluorescence imaging in ovarian cancer patients allowed detection of 57 lesions of which 44 (77%) appeared malignant on histopathology. Seven out of these 44 (16%) were not detected with inspection/palpation. Histopathology demonstrated concordance between fluorescence and FRα- and tumor status. Fluorescence imaging in breast cancer patients, allowed detection of tumor-specific fluorescence signal. At the 500nm wavelength, autofluorescence of normal breast tissue was present to such extent that it interfered with tumor identification. Conclusions: FRα is a favorable target for fluorescence-guided surgery as EC17 produced a clear fluorescent signal in ovarian and breast cancer tissue. This resulted in resection of ovarian cancer lesions that were otherwise not detected. Notwithstanding, autofluorescence caused false-positive lesions in ovarian cancer and difficulty in discriminating breast cancer-specific fluorescence from background signal. Optimization of the 500nm fluorophore, will minimize autofluorescence and further improve intraoperative tumor detection." @default.
• W2316581203 created "2016-06-24" @default.
• W2316581203 creator A5001992356 @default.
• W2316581203 creator A5011441632 @default.
• W2316581203 creator A5012446734 @default.
• W2316581203 creator A5016552200 @default.
• W2316581203 creator A5025042206 @default.
• W2316581203 creator A5026031837 @default.
• W2316581203 creator A5028075025 @default.
• W2316581203 creator A5028736158 @default.
• W2316581203 creator A5047227576 @default.
• W2316581203 creator A5061550014 @default.
• W2316581203 creator A5062800805 @default.
• W2316581203 creator A5083164288 @default.
• W2316581203 creator A5083201186 @default.
• W2316581203 date "2016-03-22" @default.
• W2316581203 modified "2023-10-17" @default.
• W2316581203 title "Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17" @default.
• W2316581203 cites W1486131515 @default.
• W2316581203 cites W1507264290 @default.
• W2316581203 cites W1570518064 @default.
• W2316581203 cites W1871308790 @default.
• W2316581203 cites W1918904712 @default.
• W2316581203 cites W1973149256 @default.
• W2316581203 cites W1974452295 @default.
• W2316581203 cites W1977871291 @default.
• W2316581203 cites W1981734925 @default.
• W2316581203 cites W1982548635 @default.
• W2316581203 cites W1991354544 @default.
• W2316581203 cites W1993215855 @default.
• W2316581203 cites W1997168106 @default.
• W2316581203 cites W2002516695 @default.
• W2316581203 cites W2009630043 @default.
• W2316581203 cites W2014519079 @default.
• W2316581203 cites W2024856950 @default.
• W2316581203 cites W2025244200 @default.
• W2316581203 cites W2026762108 @default.
• W2316581203 cites W2038341023 @default.
• W2316581203 cites W2045181039 @default.
• W2316581203 cites W2045872241 @default.
• W2316581203 cites W2047192146 @default.
• W2316581203 cites W2049490668 @default.
• W2316581203 cites W2050973816 @default.
• W2316581203 cites W2051980540 @default.
• W2316581203 cites W2060459188 @default.
• W2316581203 cites W2067848116 @default.
• W2316581203 cites W2070194964 @default.
• W2316581203 cites W2083035675 @default.
• W2316581203 cites W2099521317 @default.
• W2316581203 cites W2106235642 @default.
• W2316581203 cites W2106767659 @default.
• W2316581203 cites W2112579958 @default.
• W2316581203 cites W2114636933 @default.
• W2316581203 cites W2116796970 @default.
• W2316581203 cites W2121129806 @default.
• W2316581203 cites W2125372543 @default.
• W2316581203 cites W2126987398 @default.
• W2316581203 cites W2143668968 @default.
• W2316581203 cites W2167077543 @default.
• W2316581203 cites W2313984291 @default.
• W2316581203 cites W4232721722 @default.
• W2316581203 cites W4297742529 @default.
• W2316581203 cites W888121792 @default.
• W2316581203 doi "https://doi.org/10.18632/oncotarget.8282" @default.
• W2316581203 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5078003" @default.
• W2316581203 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27014973" @default.
• W2316581203 hasPublicationYear "2016" @default.
• W2316581203 type Work @default.
• W2316581203 sameAs 2316581203 @default.
• W2316581203 citedByCount "109" @default.
• W2316581203 countsByYear W23165812032016 @default.
• W2316581203 countsByYear W23165812032017 @default.
• W2316581203 countsByYear W23165812032018 @default.
• W2316581203 countsByYear W23165812032019 @default.
• W2316581203 countsByYear W23165812032020 @default.
• W2316581203 countsByYear W23165812032021 @default.
• W2316581203 countsByYear W23165812032022 @default.
• W2316581203 countsByYear W23165812032023 @default.
• W2316581203 crossrefType "journal-article" @default.
• W2316581203 hasAuthorship W2316581203A5001992356 @default.
• W2316581203 hasAuthorship W2316581203A5011441632 @default.
• W2316581203 hasAuthorship W2316581203A5012446734 @default.
• W2316581203 hasAuthorship W2316581203A5016552200 @default.
• W2316581203 hasAuthorship W2316581203A5025042206 @default.
• W2316581203 hasAuthorship W2316581203A5026031837 @default.
• W2316581203 hasAuthorship W2316581203A5028075025 @default.
• W2316581203 hasAuthorship W2316581203A5028736158 @default.
• W2316581203 hasAuthorship W2316581203A5047227576 @default.
• W2316581203 hasAuthorship W2316581203A5061550014 @default.
• W2316581203 hasAuthorship W2316581203A5062800805 @default.
• W2316581203 hasAuthorship W2316581203A5083164288 @default.
• W2316581203 hasAuthorship W2316581203A5083201186 @default.
• W2316581203 hasBestOaLocation W23165812031 @default.
• W2316581203 hasConcept C121608353 @default.
• W2316581203 hasConcept C126322002 @default.
• W2316581203 hasConcept C143998085 @default.
• W2316581203 hasConcept C2780306303 @default.
• W2316581203 hasConcept C2780427987 @default.

• next